<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-148592</identifier>
<setSpec>1130-0108</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Anal intraepitelial neoplasia: a narrative review</dc:title>
<dc:description xml:lang="en">Anal intraepitelial neoplasia (AIN) constitutes a major health problem in certain risk groups, such as patients with immunosuppression of varied origin, males who have sexual relations with other males, and females with a previous history of vaginal or cervical abnormalities in cytology. Its relationship with the human papillomavirus (HPV) infection has been well documented; however, many of the factors involved in the progression and regression of the viral infection to dysplasia and anal carcinoma are unknown. AIN can be diagnosed through cytology of the anal canal or biopsy guided by high-resolution anoscopy. However, the need for these techniques in high-risk groups remains controversial. Treatment depends on the risk factors and given the high morbidity and high recurrence rates the utility of the different local treatments is still a subject of debate. Surgical biopsy is justified only in the case of progression suggesting lesions. The role of the vaccination in high-risk patients as primary prevention has been debated by different groups. However, there is no general consensus on its use or on the need for screening this population (AU)</dc:description>
<dc:creator>Elorza, Garazi</dc:creator>
<dc:creator>Enríquez-Navascués, José María</dc:creator>
<dc:creator>Velaz, Leyre</dc:creator>
<dc:creator>Saralegui, Yolanda</dc:creator>
<dc:creator>Placer, Carlos</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La neoplasia intraepitelial anal (AIN) constituye un importante problema de salud en ciertos grupos de riesgo como los  pacientes con inmunodepresión de diverso origen, varones que mantienen relaciones sexuales con otros hombres, y mujeres con antecedentes de alteraciones en la citología cervical y/o vaginal. Está bien demostrada su relación con la infección del virus del papiloma humano (HPV), sin embargo se desconocen muchos de los factores implicados en la progresión y regresión de la infección viral a la displasia y al carcinoma anal. La pruebas diagnósticas de elección son la citología del canal anal y la anuscopia de alta resolución con biopsias dirigidas, aunque existe controversia sobre la necesidad de realización de la misma en poblaciones de riesgo. El tratamiento del AIN depende de los factores de riesgo y la necesidad de tratamiento local es controvertida debido a la alta tasa de recurrencia y morbilidad de las técnicas utilizadas. La biopsia quirúrgica está justificada sólo ante lesiones macroscópicas sugestivas de progresión. La vacunación frente al HPV para una prevención primaria en pacientes de alto riesgo ha sido debatida entre diferentes grupos, sin embargo no existe consenso sobre su implantación ni tampoco sobre la realización de un cribado en esta población (AU)</dc:description>
<dc:source>Rev Esp Enferm Dig;108(1): 31-39, ene. 2016. tab</dc:source>
<dc:identifier>ibc-148592</dc:identifier>
<dc:title xml:lang="es">Neoplasia intraepitelial anal: una revisión de conjunto</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d35997^s22026</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d3603^s22048</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d2330^s22044</dc:subject>
<dc:subject>^d24758^s22010</dc:subject>
<dc:subject>^d11758^s22045</dc:subject>
<dc:subject>^d2330^s22011</dc:subject>
<dc:subject>^d3603^s22011</dc:subject>
<dc:subject>^d24758^s22044</dc:subject>
<dc:subject>^d2330^s22053</dc:subject>
<dc:subject>^d35997^s22053</dc:subject>
<dc:subject>^d13106^s22031</dc:subject>
<dc:subject>^d13106^s22011</dc:subject>
<dc:subject>^d13106^s22056</dc:subject>
<dc:subject>^d35997^s22044</dc:subject>
<dc:subject>^d2330^s22057</dc:subject>
<dc:subject>^d35997^s22012</dc:subject>
<dc:subject>^d24758^s22031</dc:subject>
<dc:subject>^d11758^s22011</dc:subject>
<dc:type>article</dc:type>
<dc:date>201601</dc:date>
</metadata>
</record>
</ibecs-document>
